TCL Archive NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units March 1, 2013
TCL Archive Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies September 25, 1998
TCL Archive Hard imes For Cancer Control – Six Contracts Ended; Rochester’s Community Proposal Rejected October 1, 1976
TCL Archive Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards February 7, 1997
TCL Archive Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial January 31, 2014
